Zynerba Pharmace Stock Price, News & Analysis

Zynerba Pharmaceuticals (Nasdaq: ZYNE) presented findings at the 55th Gatlinburg Conference, highlighting the long-term safety and efficacy of Zygel for treating children with Fragile X syndrome and 22q11.2 deletion syndrome. The interim results from the ongoing trials indicate Zygel shows sustained improvements over extended treatment periods. Specifically, children with complete methylation of their FMR1 gene experienced significant enhancements in social avoidance metrics. Additionally, Zygel demonstrated statistically significant improvements in anxiety and behavioral symptoms through 38 weeks of treatment in the INSPIRE trial. The company is actively enrolling participants for its Phase 3 RECONNECT trial, aimed at further demonstrating Zygel's efficacy.

Zynerba Pharmaceuticals (Nasdaq: ZYNE) announced its participation in the 55th Gatlinburg Conference, scheduled for April 10-13, 2023, in Kansas City, Mo. The company will present two posters: one on the long-term safety and sustained efficacy of ZYN002 in children with Fragile X Syndrome on April 12, and another on an open-label study of ZYN002 for children with 22q11.2 deletion syndrome on April 13. Zygel, Zynerba's transdermal cannabinoid gel, aims to treat behavioral symptoms associated with these conditions and has received Fast Track designation from the FDA.

Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) reported its 2022 financial results, highlighting a net loss of $35.0 million and cash reserves of $50.6 million as of December 31, 2022. The company is focused on enrolling patients in its Phase 3 RECONNECT trial for Zygel™, targeting Fragile X syndrome, with topline results expected in the first half of 2024. The European Commission granted orphan drug designation for cannabidiol in 22q11.2 deletion syndrome. Zynerba has issued shares under sales agreements, generating approximately $7.8 million in gross proceeds in 2022. The company projects sufficient cash runway into mid-2024 to support its operations.

Zynerba Pharmaceuticals (Nasdaq: ZYNE) announced that it has no cash deposits or securities at Silicon Valley Bank, ensuring its financial security amid concerns affecting other firms. The company specializes in innovative transdermal cannabinoid therapies for neuropsychiatric disorders, including Fragile X syndrome and 22q11.2 deletion syndrome. This communication is vital for investors, reaffirming that Zynerba is not impacted by any potential liquidity issues related to Silicon Valley Bank. The firm remains committed to advancing its clinical development programs and providing solutions for patients with chronic health conditions.

Zynerba Pharmaceuticals (Nasdaq: ZYNE), a leader in transdermal cannabinoid therapies for orphan neuropsychiatric disorders, announced that Armando Anido, Chairman and CEO, will present at the Oppenheimer 33rd Annual Healthcare Conference on March 13, 2023, at 4:40 p.m. ET. The company will also host investor meetings during this event. Investors can arrange virtual meetings through the conference coordinator. A webcast of the presentation will be accessible on Zynerba's website and available on-demand for 60 days post-event.

Zynerba is dedicated to enhancing the lives of patients with severe chronic conditions, including Fragile X syndrome and 22q11.2 deletion syndrome.

Zynerba Pharmaceuticals, a leader in transdermal cannabinoid therapies for neuropsychiatric disorders, announced that Armando Anido, its CEO, will present at Cowen's 43rd Annual Health Care Conference on March 8, 2023, at 2:50 PM ET. The event will take place at the Boston Marriott Copley Place in Massachusetts. Interested investors can arrange meetings with company management through the conference coordinator. An archived webcast of the presentation will be available for 60 days on the Zynerba website.

Zynerba focuses on improving lives for patients with chronic conditions like Fragile X syndrome.

Zynerba Pharmaceuticals (Nasdaq: ZYNE) announced the publication of a paper in the Journal of Neurodevelopmental Disorders, highlighting the endocannabinoid system's role in Fragile X syndrome (FXS) and the potential of cannabidiol (Zygel) as a treatment. The Phase 3 CONNECT-FX trial showed significant behavioral symptom reduction in patients with ≥90% methylation of the FMR1 gene. The findings support ongoing clinical trials, including the pivotal Phase 3 RECONNECT trial.